The adalimumab is a human, recombinant antibody, which is able to give an effective therapy modality in patients with rheumatoid arthritis, polyarticular juvenil idiopathic arthritis, psoriasis, arthritis psoriatica, spondylitis ankylopoetica, as well as with Crohn-disease. The adalimumab has got a high affinity binding to tumor necrosis factor (TNF) -alfa, this way it inhibits the interactions with TNF and its receptors (soluble and membrane associated). It could be well tolerated and safe, it improves the the quality of life in patients. The possible side effects can be decreased by the careful observation and usual control of patients. The authors discuss in details the publications connected with adalimumab in the above mentioned diseases.
ASJC Scopus subject areas